Social Media Ideas for Fulcrum Therapeutics

Why is Fulcrum Therapeutics stock rallying today?

Slate, Fulcrum to combine in reverse merger

Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.

Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials

Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical d...

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drug...

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve...

Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine

Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering...

Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday

Actimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 millio...

Travere Therapeutics Turns a Rare Disease Approval into Two Quarters of Accelerating Sales

The Food and Drug Administration granted Travere Therapeutics full approval for FILSPARI in focal segmental glomerulosclerosis on April 13, 2026, the drug’s second full approval af...

After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platform

After announcing the “tough but necessary” decision to lay off some employees last year, Frontier Medicines is looking to the future by advancing more cancer drugs into the clinic...

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its priz...

Skye and Redx form new entity with $125M to advance fibrosis assets

Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new publ...

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

Del-desiran failed the Phase III HARBOR trial (NCT06411288) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time...

Epicrispr raises $90M to rewrite treatment of rare muscle disease

Epicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medi...

Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug

Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a rece...

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)

AbCellera, Vertex partner on next-gen T-cell engagers

The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medi...

Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program

Arpeggio Biosciences’ eight-year song has come to an end, as the transcriptome biotech’s CEO admitted the that company’s Nrf2 program had begun to “unravel.”

Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug

Werewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and has raised $150 million, positionin...

<![CDATA[Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly]]>

ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

<![CDATA[Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb]]&...

Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor

A phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary and secondary endpoints. But the biotech is still moving the TYK2 inhibitor into phase 3 in the autoimmune d...

Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test

The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of...

Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylos...

HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company...